By Nishant Arora
Fifteen years ago when scientists the world over were still trying to understand the health benefit of the human stem-cell technology, an Indian specialist in the field took a step that left many in the scientific community bemused.
In 2000, she developed two purely human embryonic stem cell lines from just one fertilized egg. The cell-based therapy has since helped many patients improve their quality of life and live a stress-free life.
“I have been working in this field for over 15 years. Of these, 13 years have been spent in clinical application also. As a doctor, it is very satisfying to see improvements in the condition of your patient. However, since cell-based therapy is a very new field, greater education of the masses is required,” Dr. Geeta Shroff, founder and director of Nutech Mediworld, told IANS in an interview.
She offers treatment to patients suffering from conditions that are currently labelled as incurable. At Nutech Mediworld in New Delhi, she says her team has successfully treated over 1,400 patients from India and abroad. She has also written about her research in international journals.
Shroff recently treated a 38-year-old woman who was getting bruises all over her body and suffered from excessive fatigue. She was diagnosed as suffering from aplastic anaemia with severe anaemia and severe thrombocytopenia – deficiency of platelets in the blood, which causes bleeding into the tissues, bruising and slow blood clotting after injury.
The diagnosis was devastating because the condition leads to fatality. She had already undergone multiple blood transfusions. She was prescribed steroids and was in line for anti-thymocyte globulin (ATG) treatment which has low therapeutic safety and many side effects.
The inconvenience and stress of the blood transfusions, coupled with excessive fatigue, left her with little energy for anything else. Her platelet count continued to be less than 20,000.
“The patient heard about the cell-based therapy being offered by us and decided to undergo it. Today, she no longer requires blood transfusion and is leading a steroid-free life. Her CBC remains normal with Platelet count above 60,000. She no longer gets bruises easily,” Shroff said.
For the therapy, the two cell lines are derived from a single fertilized ovum obtained during a natural in vitro-fertilization (IVF) cycle with due consent.
Chromosomally stable cell lines free from contaminants are used.
“This technology does not require the administration of immunosuppressants. The ready to use form can be stored for more than six months and can be transported easily under temperature controlled conditions,” said the doctor.
The treatment is safe and effective and the results are not only replicable, but are also statistically significant, she said.
“As with all treatments, the cost of the therapy is based on the treatment protocol. This is further based on the diagnosis, patient’s condition, duration of illness, age, etc.,” she added.
Internationally, there have been several studies in the recent past on human embryonic stem cell therapy that paves the way for patient therapies.
According to a study published in the journal Scientific Reports in November last year by the scientists at the University of Edinburgh, stem cells that have been specifically developed for use as clinical therapies are fit for use in patients.
Dr Shroff is confident that the therapy has the potential of treating many of mankind’s worst known afflictions.
“It is our mission to see human embryonic stem cell therapy as the first line of treatment for many of mankind’s worst afflictions. Our technology has been patented in 66 countries, including the US, Singapore, Australia, Japan and Korea,” Dr Shroff said. (IANS)(Photo: westonmedicalhealth.com)